Gyre Therapeutics Inc (NASDAQ: GYRE) on Tuesday, plunged -30.21% from the previous trading day, before settling in for the closing price of $12.28. Within the past 52 weeks, GYRE’s price has moved between $8.26 and $19.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 309.98% annually for the last half of the decade. The company achieved an average annual earnings per share of 740.00%. With a float of $16.16 million, this company’s outstanding shares have now reached $85.77 million.
In an organization with 4 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 96.33%, operating margin of 15.28%, and the pretax margin is 21.95%.
Gyre Therapeutics Inc (GYRE) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Gyre Therapeutics Inc is 81.17%, while institutional ownership is 2.08%. The most recent insider transaction that took place on Mar 14 ’25, was worth 24,620. In this transaction President of this company sold 2,000 shares at a rate of $12.31, taking the stock ownership to the 2,831,260 shares. Before that another transaction happened on Mar 13 ’25, when Company’s President sold 2,000 for $11.80, making the entire transaction worth $23,600. This insider now owns 2,833,260 shares in total.
Gyre Therapeutics Inc (GYRE) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 740.00% per share during the next fiscal year.
Gyre Therapeutics Inc (NASDAQ: GYRE) Trading Performance Indicators
Gyre Therapeutics Inc (GYRE) is currently performing well based on its current performance indicators. A quick ratio of 3.29 was reported for the most recent quarter.
Technical Analysis of Gyre Therapeutics Inc (GYRE)
Let’s dig in a bit further. During the last 5-days, its volume was 0.22 million. That was better than the volume of 98761.0 it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 44.71%. Additionally, its Average True Range was 1.14.
During the past 100 days, Gyre Therapeutics Inc’s (GYRE) raw stochastic average was set at 0.81%, which indicates a significant decrease from 1.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 158.48% in the past 14 days, which was higher than the 95.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.25, while its 200-day Moving Average is $12.22. However, in the short run, Gyre Therapeutics Inc’s stock first resistance to watch stands at $10.55. Second resistance stands at $12.53. The third major resistance level sits at $13.57. If the price goes on to break the first support level at $7.54, it is likely to go to the next support level at $6.50. The third support level lies at $4.52 if the price breaches the second support level.
Gyre Therapeutics Inc (NASDAQ: GYRE) Key Stats
Market capitalization of the company is 735.50 million based on 93,521K outstanding shares. Right now, sales total 113,450 K and income totals -92,930 K. The company made 25,490 K in profit during its latest quarter, and 1,120 K in sales during its previous quarter.
